home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 10/18/22

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - Qualigen Therapeutics to Present at LD Micro Main Event XV

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
QLGN - Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium

CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

QLGN - Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Posters include data regarding 1) m ode of action , and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing trea...

QLGN - Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
QLGN - Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q2 GAAP EPS of -$0.11 beats by $0.06 . Revenue of $1.4M (+25.0% Y/Y) beats by $0.05M . As of June 30, 2022, Qualigen Therapeutics had $9.7 million in cash. The Company believes its cash is sufficient to ...

QLGN - Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Q2 2022 FastPack ® Sales increased approximately 28 %, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN- 247 oncology therapeutic programs and acquisition of majori...

QLGN - Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
QLGN - Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen Therapeutics ( NASDAQ: QLGN ) on Friday filed for a mixed shelf offering of up to $150M. The company disclosed the offering in a S-3 filing with the U.S. SEC after hours. The offering consists of a combination of common stock, preferred stock, debt securit...

QLGN - Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Qualigen Therapeutics ( NASDAQ: QLGN ) on Wednesday said it would partner China-based Hande Sciences to scale-up manufacturing to support investigational new drug application enabling studies for its QN-302 inhibitor platform. QLGN is developing QN-302 as a potential treat...

QLGN - Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
Previous 10 Next 10